| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Over the last 12 months, insiders at Adial Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Adial Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Adial Pharmaceuticals, Inc. have bought $50,930 and sold $375,000 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 700 shares for transaction amount of $1,918 was made by Schuyler Kevin (director) on 2023‑09‑29.
| 2023-09-29 | Schuyler Kevin | director | 700 0.0566% | $2.74 | $1,918 | -50.18% | ||
| 2021-12-30 | Newman James W. Jr. | director | 25,000 0.1356% | $2.69 | $67,300 | -53.00% | ||
| 2021-11-30 | Stilley William B. III | Chief Executive Officer | 10,600 0.0565% | $2.75 | $29,179 | -51.80% | ||
| 2021-11-29 | Stilley William B. III | Chief Executive Officer | 10,000 0.0544% | $2.59 | $25,892 | -47.27% | ||
| 2021-11-26 | Newman James W. Jr. | director | 10,000 0.0538% | $2.85 | $28,500 | -52.28% | ||
| 2021-04-06 | Sale | Johnson Bankole A. | Chief Medical Officer | 150,000 0.8494% | $2.50 | $375,000 | +4.38% | |
| 2020-08-20 | Sale | Johnson Bankole A. | Chief Medical Officer | 350,000 2.0553% | $1.21 | $423,500 | +47.02% | |
| 2020-03-27 | Newman James W. Jr. | director | 19,644 0.1848% | $1.36 | $26,769 | +23.91% | ||
| 2020-03-26 | Stilley William B. III | Chief Executive Officer | 12,652 0.1363% | $1.47 | $18,598 | +31.54% | ||
| 2020-03-25 | Stilley William B. III | Chief Executive Officer | 12,348 0.1072% | $1.13 | $13,953 | +37.90% | ||
| 2019-12-12 | Sale | Johnson Bankole A. | Chief Medical Officer | 150,000 0.8506% | $1.00 | $150,000 | -7.44% | |
| 2019-03-29 | Johnson Bankole A. | Chief Medical Officer | 33,100 0.4057% | $3.47 | $114,801 | -50.44% | ||
| 2019-03-28 | Johnson Bankole A. | Chief Medical Officer | 40,000 0.4706% | $3.15 | $125,808 | -47.53% | ||
| 2018-07-31 | Stilley William B. III | Chief Executive Officer | 80,000 1.8029% | $5.00 | $400,000 | -28.75% | ||
| 2018-07-31 | Schuyler Kevin | director | 180,000 2.0282% | $2.50 | $450,000 | -28.75% | ||
| 2018-07-31 | Newman James W. Jr. | director | 20,000 0.4507% | $5.00 | $100,000 | -28.75% | ||
| 2018-07-31 | Gilliland Robertson H. | director | 14,000 0.3155% | $5.00 | $70,000 | -28.75% | ||
| 2018-07-31 | Goodman Tony | director | 14,000 0.3549% | $5.63 | $78,750 | -28.75% | ||
| 2018-07-31 | Johnson Bankole A. | 1,400 0.0316% | $5.00 | $7,000 | -28.75% |
| Stilley William B. III | Chief Executive Officer | 937646 3.9089% | $289,357.56 | 5 | 0 | <0.0001% |
| Johnson Bankole A. | Chief Medical Officer | 548336 2.2859% | $169,216.49 | 3 | 3 | <0.0001% |
| Gilliland Robertson H. | director | 109424 0.4562% | $33,768.25 | 1 | 0 | <0.0001% |
| Newman James W. Jr. | director | 50221 0.2094% | $15,498.20 | 4 | 0 | <0.0001% |
| Goodman Tony | director | 8755 0.0365% | $2,701.79 | 1 | 0 | <0.0001% |
| Schuyler Kevin | director | 700 0.0029% | $216.02 | 2 | 0 | <0.0001% |
$13,664,154 | 40 | -70.35% | $7.07M | |
$1,029,337 | 36 | -28.38% | $6.62M | |
$29,635,355 | 27 | 9.05% | $6.47M | |
$63,749,694 | 24 | -12.24% | $8.06M | |
$547,862 | 19 | -29.82% | $7.89M | |
Adial Pharmaceuticals, Inc. (ADIL) | $1,556,551 | 15 | -25.43% | $7.4M |
$742,412 | 14 | -50.36% | $8.41M | |
$945,055 | 14 | -8.25% | $7.94M | |
$389,864 | 11 | 12.52% | $8.75M | |
$120,379 | 10 | -24.48% | $7.45M | |
$20,715,938 | 10 | -42.51% | $6.17M | |
$309,830 | 10 | -55.78% | $8.43M | |
$90,087 | 9 | 20.06% | $6.67M | |
$8,971,546 | 8 | 6.18% | $5.61M | |
$84,058 | 7 | -61.66% | $7.11M | |
$159,974 | 7 | -18.60% | $7.61M | |
$76,299 | 4 | 11.60% | $6.47M | |
$28,395 | 3 | 3.48% | $8.2M | |
$4,423 | 2 | 3.27% | $6.04M |
| Increased Positions | 8 | +47.06% | 411,324 | +175.25% |
| Decreased Positions | 6 | -35.29% | 37,945 | -16.17% |
| New Positions | 3 | New | 166,632 | New |
| Sold Out Positions | 3 | Sold Out | 17,476 | Sold Out |
| Total Postitions | 19 | +11.76% | 608,084 | +159.08% |
| Geode Capital Management, Llc | $52.00 | 0.68% | 164,127 | +95,277 | +138.38% | 2025-09-30 |
| Vanguard Group Inc | $49.00 | 0.65% | 156,024 | +142,865 | +1,085.68% | 2025-09-30 |
| Citadel Advisors Llc | $45.00 | 0.6% | 143,791 | +143,791 | New | 2025-09-30 |
| Manchester Capital Management Llc | $15.00 | 0.2% | 48,097 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $9.00 | 0.12% | 27,770 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $6.00 | 0.08% | 18,758 | +6,363 | +51.34% | 2025-09-30 |
| Two Sigma Securities, Llc | $4.00 | 0.05% | 12,841 | +12,841 | New | 2025-09-30 |
| Jane Street Group, Llc | $4.00 | 0.05% | 12,341 | -12,521 | -50.36% | 2025-09-30 |
| Hrt Financial Lp | $4.00 | 0.05% | 11,191 | -7,899 | -41.38% | 2025-09-30 |
| Private Management Group Inc | $3.00 | 0.04% | 10,000 | +10,000 | New | 2025-09-30 |